Ptc Therapeutics (PTCT) Enterprise Value (2013 - 2026)

Ptc Therapeutics' Enterprise Value history runs 15 years deep, the most recent figure standing at -$2.2 billion for Q2 2026.

• In Q2 2026, Enterprise Value fell 12.06% year-over-year to -$2.2 billion; the TTM figure through Jun 2026 stood at -$2.2 billion (down 12.06% YoY), while the FY2025 annual figure was -$1.9 billion, down 70.69% from the prior year.
• Enterprise Value for Q2 2026 stood at -$2.2 billion, down from -$1.9 billion in the prior quarter.
• The five-year high for Enterprise Value was -$286.3 million in Q1 2023, with the low at -$2.2 billion in Q2 2026.
• The 5-year median for Enterprise Value is -$949.1 million (2024), against an average of -$1.1 billion.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value jumped 66.77% in 2022, then tumbled 243.73% in 2024.
• Ptc Therapeutics' Enterprise Value stood at -$410.7 million in 2022, then plunged by 113.47% to -$876.7 million in 2023, then fell by 29.99% to -$1.1 billion in 2024, then sank by 70.69% to -$1.9 billion in 2025, then retreated by 14.58% to -$2.2 billion in 2026.
• Business Quant data shows PTCT's Enterprise Value at -$2.2 billion in Q2 2026, -$1.9 billion in Q1 2026, and -$1.9 billion in Q4 2025.